Helmholtz Gemeinschaft


The SUMO pathway in pancreatic cancer: insights and inhibition

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Item Type:Review
Title:The SUMO pathway in pancreatic cancer: insights and inhibition
Creators Name:Schneeweis, C. and Hassan, Z. and Schick, M. and Keller, U. and Schneider, G.
Abstract:An urgent medical need to develop novel treatment strategies for patients with pancreatic ductal adenocarcinoma (PDAC) exists. However, despite various efforts in the histopathological and molecular subtyping of PDAC, novel targeted or specific therapies have not been established. Posttranslational modifications (PTMs) with ubiquitin-like proteins, including small ubiquitin-like modifiers (SUMOs), mediate numerous processes that can contribute to the fitness and survival of cancer cells. The contribution of SUMOylation to transcriptional control, DNA repair pathways, mitotic progression, and oncogenic signalling has been described. Here we review functions of the SUMO pathway in PDAC, with a special focus on its connection to an aggressive subtype of the disease characterised by high MYC activity, and discuss SUMOylation inhibitors under development for precise PDAC therapies.
Keywords:Cell Survival, Cysteine Endopeptidases, DNA Repair, Enzyme Inhibitors, Mitosis, Pancreatic Ductal Carcinoma, Pancreatic Neoplasms, Poly-ADP-Ribose Binding Proteins, Post-Translational Protein Processing, Promyelocytic Leukemia Protein, Protein Inhibitors of Activated STAT, Proto-Oncogene Proteins c-myc, SUMO-1 Protein, Signal Transduction, Small Ubiquitin-Related Modifier Proteins, Sumoylation, Synthetic Lethal Mutations, Ubiquitin-Conjugating Enzymes, Ubiquitins
Source:British Journal of Cancer
Publisher:Nature Publishing Group
Page Range:531-538
Date:2 February 2021
Official Publication:https://doi.org/10.1038/s41416-020-01119-6
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library